雅克科技(002409.SZ):擬斥15億元在湖州投建“年產3.9萬噸半導體核心材料項目”
格隆匯2月28日丨雅克科技(002409.SZ)公佈,為進一步完善全資子公司浙江華飛電子基材有限公司(簡稱“華飛電子”)的產業鏈條,提高企業競爭力,促進企業健康有序發展,華飛電子擬投資建設“年產3.9萬噸半導體核心材料項目”,項目總用地約82畝,總投資約15億元,其中固定資產投資約13億元,分三期建設,總建設週期約為5年,資金來源主要為企業自籌。
通過前期洽談溝通,華飛電子擬與湖州南太湖新區管理委員會簽署《合作協議書》,在湖州南太湖新區投資建設“年產3.9萬噸半導體核心材料項目”。項目名稱和建設內容最終以相關政府主管機關的批准文件為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.